KMT2A rearrangement + CD19 positive
|
ALL
|
KMT2A rearrangement + CD19 positive
|
ALL
|
tisagenlecleucel-T Sensitive: C3 – Early Trials
|
tisagenlecleucel-T Sensitive: C3 – Early Trials
|
KMT2A rearrangement + CD19 positive
|
ALL
|
KMT2A rearrangement + CD19 positive
|
ALL
|
CD19-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials
|
CD19-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials
|